Paul Maciocia
Paul Maciocia
Verified email at
Cited by
Cited by
Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies
PM Maciocia, PA Wawrzyniecka, B Philip, I Ricciardelli, AU Akarca, ...
Nature medicine 23 (12), 1416-1423, 2017
An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma
L Lee, B Draper, N Chaplin, B Philip, M Chin, D Galas-Filipowicz, ...
Blood, The Journal of the American Society of Hematology 131 (7), 746-758, 2018
Pain assessment in the paediatric Emergency Department: whose view counts?
PM Maciocia, EM Strachan, AR Akram, RE Hendrie, DN Kelly, A Kemp, ...
European Journal of Emergency Medicine 10 (4), 264-267, 2003
Real‐world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi‐centre UK experience
N Maciocia, A Melville, S Cheesman, F Sharpley, K Ramasamy, ...
British journal of haematology 176 (6), 908-917, 2017
Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia
PM Maciocia, PA Wawrzyniecka, NC Maciocia, A Burley, T Karpanasamy, ...
Blood, The Journal of the American Society of Hematology 140 (1), 25-37, 2022
Treatment of diffuse large B‐cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS‐penetrating R‐IDARAM chemotherapy
P Maciocia, M Badat, S Cheesman, S D'Sa, R Joshi, J Lambert, ...
British journal of haematology 172 (4), 545-553, 2016
Protein-based T-cell receptor knockdown
P Martin, P Maciocia, B Grimshaw
US Patent 10,730,942, 2020
Chimeric antigen receptor T cells for gamma–delta T cell malignancies
PA Wawrzyniecka, L Ibrahim, G Gritti, MA Pule, PM Maciocia
Leukemia 36 (2), 577-579, 2022
Chimeric antigen receptor
M Pulé, P Maciocia
US Patent App. 15/123,287, 2017
Anti-CD1a CAR T cells to selectively target T-ALL
PM Maciocia, MA Pule
Blood, The Journal of the American Society of Hematology 133 (21), 2246-2247, 2019
Inflammatory signaling in pulmonary arterial hypertension: The controversial role of CRP, and the search for new therapies
PM Maciocia
Cardiovascular therapeutics 28 (1), 1-4, 2010
Structure guided engineering of highly specific chimeric antigen receptors for the treatment of T cell lymphomas
S Onuoha, M Ferrari, A Bulek, R Bughda, S Manzoor, S Srivastava, B Ma, ...
Blood 132, 1661, 2018
Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region
P Martin, P Maciocia
Anti-CD21 chimeric antigen receptor (CAR)-T cells for t cell acute lymphoblastic leukaemia (T-ALL)
NC Maciocia, A Burley, F Nannini, P Wawrzyniecka, M Neves, ...
Blood 138, 902, 2021
T-cell receptor constant region 1 antibody or T-cell receptor constant region 2 antibody
M Pulé, S Onuoha, AM Neves, M Ferrari, P Maciocia
US Patent 11,945,867, 2024
Methods of depleting malignant T-cells
M Pulé, P Maciocia
US Patent 11,385,233, 2022
Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies
M Ferrari, M Righi, V Baldan, P Wawrzyniecka, A Bulek, A Kinna, B Ma, ...
Nature Communications 15 (1), 1583, 2024
Targeting TRBC1 and 2 for the treatment of T cell lymphomas
M Ferrari, V Baldan, P Ghongane, A Nicholson, R Bughda, Z Akbar, ...
Cancer Research 80 (16_Supplement), 2183-2183, 2020
A protein-based method to develop allogeneic chimeric antigen receptor T-cells
P Maciocia, P Wawrzyniecka, L Kassimatis, M Pule
Blood 132, 700, 2018
Targeting T-cell receptor β-constant domain for immunotherapy of T-cell malignancies
PM Maciocia, P Wawrzyniecka, B Philip, I Ricciardelli, AU Akarca, ...
Blood 128 (22), 811, 2016
The system can't perform the operation now. Try again later.
Articles 1–20